Pharma Or Biotech – Which Innovates Better?
This article was originally published in The Pink Sheet Daily
Executive Summary
In part four of this series of seven articles, biopharma CEO participants discuss the differences between engineering and drug development.
You may also be interested in...
Pharma Or Biotech – Which Innovates Better? (Part 5 of 7)
In part five of this CEO roundtable discussion, Regulus CEO Kleanthis Xanthopolos says a 'Roman army' model works better for drug discovery.
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf